Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.

Détails

ID Serval
serval:BIB_175E929F3084
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Périodique
Journal of immunotherapy
Auteur(s)
Meijer S.L., Dols A., Jensen S.M., Hu H.M., Miller W., Walker E., Romero P., Fox B.A., Urba W.J.
ISSN
1524-9557
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
30
Numéro
5
Pages
533-543
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Patients with stage I-III melanoma were vaccinated with the modified HLA-A2-binding gp100(209-2M)-peptide after complete surgical resection of their primary lesion and sentinel node biopsy. Cytoplasmic interferon-gamma production by freshly thawed peripheral blood mononuclear cells (direct ex vivo analysis) or by peripheral blood mononuclear cells subjected to 1 cycle of in vitro sensitization with peptide, interleukin-2, and interleukin-15 was measured following restimulation with the modified and native gp100 peptides, and also A2gp100 melanoma cell lines. Peptide-reactive and tumor-reactive T cells were detected in 79% and 66% of selected patients, respectively. Patients could be classified into 3 groups according to their vaccine-elicited T-cell responses. One group of patients responded only to the modified peptide used for immunization, whereas another group of patients reacted to both the modified and native gp100 peptides, but not to naturally processed gp100 antigen on melanoma cells. In the third group of patients, circulating CD8 T cells recognized A2gp100 melanoma cell lines and also both the modified and native peptides. T cells with a low functional avidity, which were capable of lysing tumor cells only if tumor cells were first pulsed by the exogenous administration of native gp100(209-217) peptide were identified in most patients. These results indicate that vaccination with a modified gp100 peptide induced a heterogeneous group of gp100-specific T cells with a spectrum of functional avidities; however, high avidity, tumor-reactive T cells were detected in the majority of patients.
Mots-clé
Antigens, Neoplasm/immunology, CD8-Positive T-Lymphocytes/immunology, Cancer Vaccines/immunology, Cancer Vaccines/therapeutic use, Cell Line, Tumor, Humans, Interferon-gamma/biosynthesis, Lymphocytes, Tumor-Infiltrating/immunology, Melanoma/immunology, Melanoma/therapy, Membrane Glycoproteins/immunology, Skin Neoplasms/immunology, Skin Neoplasms/therapy
Pubmed
Web of science
Création de la notice
28/01/2008 11:28
Dernière modification de la notice
20/08/2019 12:47
Données d'usage